Dignify Therapeutics, LLC — SEC Form D Filing
Dignify Therapeutics, LLC filed an SEC Form D on September 25, 2026, reporting $800K raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 25, 2026
- Amount reported
- $800K
- Round stage
- Seed, because an $800,000 debt round is typical for an early-stage pharmaceutical company funding preclinical validation and initial regulatory filings.
- Industry
- Pharmaceuticals
- Website
- https://dignifytherapeutics.com
What the company does
Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients suffering from spinal cord injuries, multiple sclerosis, and spina bifida experience neurogenic bladder and bowel dysfunction, stripping them of their independence and causing frequent, severe urinary tract infections.
Solution
Dignify Therapeutics is developing novel, on-demand pharmaceutical compounds designed to restore voluntary bladder and bowel voiding without the need for invasive catheterization.
Why now
Recent breakthroughs in targeting specific neurotransmitter receptors coincide with an urgent regulatory and clinical push to reduce catheter-associated urinary tract infections in healthcare facilities.
Source: SEC EDGAR Form D filing